"Zotero Workshop"

Abstract:

In this session, BME grad students will receive a brief introduction to general library services and literature searching. After that, they will be introduced to Zotero, a reference management tool. Zotero can help researchers collect, organize, annotate, share, and cite research. Using a citation management tool saves researchers hours of time and lots of frustration. Participants are encouraged to bring a laptop so they can start using Zotero during the session.

Bio:

Becca Greenstein (she/they) is the STEM Librarian at Northwestern University Libraries and liaison to Mathematics, Statistics, Biological Sciences, and Biomedical Engineering, where she works with researchers at all levels finding, organizing, evaluating, and citing resources for their research and coursework. Outside of work, they enjoy rock climbing, baking, volunteering, biking, and spoiling their cat, Helix.

Related Info

Register Now

Building Laboratories on Motes of Dust to Scale Life Science Research 1000-fold

Abstract

Modern biology increasingly depends on running huge numbers of experiments to understand how living cells work and how we can better treat disease. But today’s laboratory tools were largely designed for experiments done one at a time, or at best, in small batches. In this talk, I will describe our efforts to rethink the laboratory itself by shrinking it down to the size of a single microscopic particle. We are developing what we call “Lab on a Particle” technologies: millions of tiny, engineered particles—smaller than a grain of dust—that each act as a self-contained laboratory. These particles can hold individual cells, capture molecules they produce, and carry out biochemical reactions, all while being processed and sorted using standard lab instruments. In effect, each particle becomes a smart test tube that runs its own experiment in parallel with millions of others. I will first explain how these particles are designed and manufactured, and how we program their surfaces to interact with cells and biomolecules. I will then show how this approach enables powerful new applications, including discovering therapeutic antibodies and T-cell receptors, studying how pairs of cells communicate, and evolving proteins with new
functions. By compressing entire laboratory workflows onto individual particles, these technologies allow us to perform experiments at scales that were previously impractical or impossible, often increasing throughput by orders of magnitude. This shift not only accelerates drug and diagnostic discovery, but also generates the large, functionally rich datasets needed to train modern artificial intelligence models in biology. Together, “Lab on a Particle” systems offer a path toward faster, more scalable, and more insightful life science research.

Bio

Dino Di Carlo is the Armond and Elena Hairapetian Professor of Bioengineering at UCLA, serial entrepreneur and inventor. He serves in academic leadership roles as the Chair of the Bioengineering Department and Deputy Director of a National Science Foundation Engineering Research Center. He is an author on >200 peer-reviewed articles and an inventor on >80 issued patents in the U.S. and across the world. His research focuses on the interface between micro & nanotechnology, information technology, and the life sciences. He also has served in business leadership roles. He co-founded several companies in the diagnostics, medical device, and biotech/pharmaceutical industries and continues to serve on the board of directors of many of these companies, and as a scientific advisor and mentor to startups, including Cytovale, Tempo Therapeutics, and Partillion Bioscience. His inventions are incorporated into commercial medical devices, such as Cytovale's IntelliSepTM test, which is the first test approved by the FDA to detect sepsis early in the emergency department, and Tempo Therapeutics’ MAP Wound MatrixTM, which has shown efficacy in humans to regenerate tissue in large wounds. Other inventions from his lab scale and automate life science research, such as Nanovial technology from Partillion Bioscience, which allows antibody drug developers to rapidly discover new antibody sequences, accelerating life-saving drugs to the clinic. He has received numerous awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor bestowed upon young scientists and engineers in the U.S.

Related Info

Register Now

Heart Regeneration and Graft Associated Arrythmia in Large Mammals

Abstract

Despite ongoing improvements in the management of cardiac disease, patients with severe acute myocardial infarction (AMI) often progress to end-stage congestive heart failure, which remains one of the most significant problems in public health. From molecular
and cellular perspective, heart failure is caused by the loss of cardiomyocytes—the fundamental contractile units of the heart. Mammalian cardiomyocytes (CM) exit the cell cycle shortly after birth and, consequently, cardiomyocytes in the hearts of adult
mammals cannot proliferate in response to injury. However, we have shown that when MI was induced in the hearts of newborn pigs on postnatal day 1 (P1), the animals recovered with significantly decreased scar size and residual fibrosis in the myocardium, and that the repair process was accompanied by increases in the expression of markers for cell-cycle activity in cardiomyocytes. Furthermore using a double injury model, when apical resection surgery (AR) was performed on P1 and AMI was induced on postnatal day 28 (P28) in the same large mammal, cardiomyocytes proliferated in response to the second injury and regenerated the damaged myocardium on P56; thus, AR on P1 extended the time window of cardiomyocyte proliferation and cardiac repair through at least to P28. We have also developed a novel cell-cycle–specific bioinformatics algorithm (CSA) for analyzing single-nucleus RNA sequencing (snRNAseq) data, which enables us to more precisely evaluate cell-cycle activity in subpopulations of cardiomyocytes. We have recently established a novel Cardiomyocyte-specific Modified mRNA Translation System (CM-SMRTs) for gene targeting, which was inspired by the effectiveness and safety of mRNA-based vaccines against SARS-CoV-2. The CM SMRTs based delivery system could efficiently target the key transcription regulator(s) and “turn-back-the-clock” of CM cell cycle, and address an unmet clinical need by providing an efficient and titratable method for transiently modifying gene expression
specifically in cardiomyocyte.

Participants will be able to discuss and explain the current understanding of the major roadblocks in myocardial regeneration, and the potential approaches to overcome these roadblocks. Participants will also share their knowledge and interests in pursuing novel
applications in this emerging field of modRNA therapeutics.

Bio

Jianyi “Jay” Zhang, M.D., Ph.D., is an international leader in myocardial bioenergetics, and cells/cell-products for cardiac repair. He is a tenured Professor of Medicine and of Engineering; T. Michael and Gillian Goodrich Endowed Chair of Engineering Leadership; and the Chair of the Department of Biomedical Engineering (BME). He came to UAB in October 2015 after he was chosen in a national search to lead the UAB BME department from the University of Minnesota Medical School, where he was the Engdahl Family Foundation Chair in Cardiovascular Regenerative Therapies, in addition to being a tenured professor of medicine, of biomedical engineering, of electrical engineering, and computer engineering. Zhang earned his M.D. from Shanghai Medical University in 1983 and his Ph.D. in biomedical engineering from the University of Minnesota in 1992. Since his arrival at UAB, the Department of Biomedical Engineering rose to the rank of top 10th in the nation in NIH funding (Blue Ridge Institute) in the past 7 years consecutively under Zhang’s leadership. Dr. Zhang has mentored 21 PhD students earned their PhD degree from University of Minnesota or UAB. Dr. Zhang’s research interests include iPS technology, heart failure, cell-products for cardiac repair. He is currently the PI of NIH multiple R01 grants, one NIH U01 grant, and one PPG that through 2027. The Zhang lab has published >200 papers in high impact journals including Circulation, Circulation Research, Cell Stem Cell, Science Translational Medicine research; he has trained more than 90 trainees, and led 18 students earning their Ph.D. He is Charter Reviewer on NIH study sections (through 2026); editorial board member for Circulation, Circulation Research, and others.

Related Info

Register Now